证券代码：688076 证券简称：ST诺泰 公告编号：2026-006 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 二、上年同期业绩情况 2024年度，公司利润总额：43,850.42万元；归属于母公司所有者的净利润：40,439.00万元；归属于母公 司所有者的扣除非经常性损益的净利润：40,782.21万元；基本每股收益：1.88元/股。 三、本期业绩变化的主要原因 （一）报告期内，公司整体销售收入增长，但受行业价格波动影响及公司固定成本增加，导致公司毛利 率水平同比有所下降。 （二）报告期内，公司根据《企业会计准则》等有关要求，对相关资产进行减值测试后，对部分资产计 提减值准备，对公司本期业绩产生影响。 （二）业绩预告情况 （1）经财务部门初步测算，公司预计2025年年度实现营业收入人民币190,000万元到200,000万元，与上 年同期（法定披露数据）相比，将增加27,519.81万元到37,519.81万元，同比增加16 ...

本期业绩变化的主要原因：(一)报告期内，公司整体销售收入增长，但受行业价格波动影响及公司固定 成本增加，导致公司毛利率水平同比有所下降。(二)报告期内，公司根据《企业会计准则》等有关要 求，对相关资产进行减值测试后，对部分资产计提减值准备，对公司本期业绩产生影响。 格隆汇1月30日丨ST诺泰(688076.SH)公布，经财务部门初步测算，公司预计2025年年度实现营业收入人 民币19亿元到20亿元，与上年同期(法定披露数据)相比，将增加2.75亿元到3.75亿元，同比增加16.94% 到23.09%。预计2025年年度实现归属于母公司所有者的净利润为3.1亿元到4.2亿元。预计2025年年度实 现归属于母公司所有者的扣除非经常性损益的净利润为3.4亿元到4.5亿元。 ...

证券代码：688076 证券简称：ST 诺泰 公告编号：2026-006 江苏诺泰澳赛诺生物制药股份有限公司 （三）本次业绩预告未经注册会计师审计。 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，公司预计 2025 年年度实现营业收入人民币 190,000 万元到 200,000 万元，与上年同期（法定披露数据）相比，将增加 27,519.81 万元到 37,519.81 万元，同比增加 16.94%到 23.09%。 （2）预计 2025 年年度实现归属于母公司所有者的净利润为 31,000 万元到 42,000 万元。 （3）预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利 润为 34,000 万元到 45,000 万元， 二、上年同期业绩情况 2024 年度，公司利润总额：43,850.42 万元；归属于母公司所有者的 ...

Group 1 - The global biotech and pharmaceutical investment and financing activities are expected to rebound significantly in 2025, driven by the robust development of innovative drug technology platforms, leading to a comprehensive recovery in the CXO industry and sustained industry prosperity into 2026 [1] - The Chinese CRO market is projected to return to a growth trajectory in 2025, with a notable 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic innovative drug market [1] - The demand side globally is showing a strong rebound, establishing a solid foundation for growth, with biotech financing reaching a historical high in Q4 2025 and multinational pharmaceutical companies experiencing a recovery in demand [1] Group 2 - WuXi AppTec (药明康德) is expected to report impressive performance in 2025, with adjusted net profit increasing by 41.3%, driven by the TIDES business, which has seen revenue growth exceeding 90% [2] - WuXi Biologics has reached a record high of 945 projects, with a 30% growth in dual monoclonal and ADC projects, indicating a strong pipeline for future commercialization [2] - WuXi AppTec's subsidiary, WuXi STA, is focusing on the ADC/XDC sector, with revenue growth exceeding 40% in 2025 and an increase in global market share to over 24% [2] Group 3 - The Chinese clinical CRO market is at a clear turning point, with Tigermed (泰格医药) benefiting from the industry recovery, as order prices stabilize and the domestic clinical pipeline grows alongside improved financing conditions [3] Group 4 - Global CDMO giants are accelerating expansion, with optimistic performance guidance; Fujifilm is expected to secure $8 billion in new orders in 2025, reflecting strong demand for large molecule CDMO services [4] - Charles River anticipates an improvement in order trends starting in H2 2025, with a forecast for revenue growth in its safety assessment business by H2 2026, serving as an early indicator of recovery in the CXO industry [4] Group 5 - Investment recommendations include focusing on leading clinical CRO platforms like Tigermed and niche leaders such as Pruis, as well as front-end CRO companies with shorter order fulfillment cycles and greater marginal elasticity [5] - In the CDMO sector, attention is advised on leading companies in the peptide supply chain, ADC beneficiaries, and those with forward-looking layouts in small nucleic acids, as well as companies with significant potential for marginal traction from large products [5]

江苏诺泰澳赛诺生物制药股份有限公司（688076） 2026 年第一次临时股东会会议资料 证券代码：688076 证券简称：ST 诺泰 江苏诺泰澳赛诺生物制药股份有限公司 2026 年第一次临时股东会会议资料 二零二六年二月 1 江苏诺泰澳赛诺生物制药股份有限公司（688076） 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会会议资料目录 | 2026 | 年第一次临时股东会会议须知 3 | | --- | --- | | 2026 | 年第一次临时股东会会议议程 5 | | | 议案一：关于向银行申请综合授信额度并提供担保的议案 7 | 一、会议期间，全体出席人员应以维护股东的合法权益、保证会议的正常 秩序和议事效率为原则，认真履行法定义务，自觉遵守会议纪律，不得侵犯公司 和其他股东的合法权益，不得扰乱股东会的正常召开秩序。 二、为保证股东会的严肃性和正常秩序，切实维护与会股东的合法权益， 除出席会议的股东（包括股东代理人，下同）、公司董事、高级管理人员、见证 律师及董事会邀请的人员外，公司有权拒绝其他人员进入会场。 三、股东出席本次股东会会议所产生的费用由其自行承担。本公司不向参 加股 ...

Core Viewpoint - The article discusses the rising trend of peptide injections among Silicon Valley elites, highlighting the unregulated and experimental nature of this practice, which is largely driven by the desire for enhanced physical performance and anti-aging effects. Group 1: Peptide Injection Trend - Silicon Valley elites are purchasing peptide compounds from Chinese factories and self-administering them, often in social settings, reflecting a culture of experimentation and a desire for improved health and performance [2][3][5]. - The most popular peptide, Semaglutide, is known for its weight loss effects, attracting many users due to its affordability compared to FDA-approved products [6][8]. - Reports indicate that the import of hormones and peptide compounds from China to the U.S. reached approximately $328 million in the first three quarters of 2025, nearly double the amount from the same period in 2024, indicating strong market demand despite safety concerns [6][8]. Group 2: Market Dynamics in China - In contrast to the injection trend in the U.S., the Chinese market primarily focuses on topical peptide products, with skincare products accounting for 89.68% of the peptide market share [9][10]. - The Chinese peptide market is projected to grow from 2.17 billion yuan in 2024 to 4.67 billion yuan by 2029, indicating a significant growth phase for the industry [17]. - Major Chinese brands like Han Shu have successfully integrated peptides into their skincare lines, achieving a market share of 34.59% in the peptide skincare segment [11][13]. Group 3: Manufacturing and Innovation - China has established itself as the global manufacturing hub for peptide products, benefiting from technological advancements and a complete industrial chain [18][20]. - Companies like Hanyu Pharmaceutical and Jiangsu Nuotai Biotech are leading the way in peptide production, with Hanyu achieving a production capacity of over ten tons annually [22][20]. - The total output value of China's peptide industry is expected to reach 247.6 billion yuan by 2030, with a projected annual growth rate of 18.4% [22].

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming compared to the ChiNext and CSI 300 indices, ranking 17th among all industries [2][36] - The report emphasizes the importance of innovation, international expansion, and overcoming challenges as key themes for investment in 2026, with a focus on BD 2.0, small nucleic acids, and supply chain opportunities [3][4] - The upcoming adjustment of the National Essential Drug List is seen as critical, aiming to address clinical needs that have evolved since the last update in 2018, particularly in pediatrics, oncology, and rare diseases [5][14] Summary by Sections National Essential Drug List Adjustment Analysis - The current drug list has not been updated since 2018, leading to a disconnect with clinical needs, necessitating a systematic adjustment [14] - The adjustment will focus on filling gaps in disease coverage, particularly in pediatrics, oncology, and rare diseases, while also solidifying the integration of collective procurement and national negotiation outcomes [18][19] - The report identifies potential beneficiaries in traditional Chinese medicine, particularly in areas with previously weak coverage [28] JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline advancements and key clinical milestones for 2026 [33] - Companies like Pfizer, Merck, and Eli Lilly presented their focus on innovative treatments and upcoming clinical trials, indicating a robust pipeline for future growth [34][35] Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance in early 2026 has shown a 7.08% increase, outperforming both the CSI 300 and ChiNext indices [36] - The report notes a shift in market sentiment, with certain innovative sectors like AI healthcare and medical robotics showing strong performance, while traditional sectors faced adjustments [2][3]

Investment Rating - The report maintains a "Hold" rating for the pharmaceutical sector [6] Core Insights - The pharmaceutical sector experienced a week-on-week decline of 0.68%, underperforming both the ChiNext Index and the CSI 300 Index, ranking 17th among all industries [2][36] - The report emphasizes a positive outlook for innovation, international expansion, and turnaround opportunities in the pharmaceutical industry, with a focus on BD 2.0, small nucleic acids, and supply chain [3][4] Summary by Sections 1. National Essential Drug List Adjustment Analysis - The adjustment of the National Essential Drug List is urgent as the current version has not been updated since 2018, leading to a disconnect with current clinical needs [14] - The new adjustments will focus on three main areas: addressing gaps in disease coverage, solidifying the integration of centralized procurement and national negotiation results, and enhancing the evidence-based standards for traditional Chinese medicine [5][14] - Potential beneficiaries from the adjustments include companies like Panlong Pharmaceutical, Guizhou Sanli, and Yiling Pharmaceutical, particularly in pediatrics, orthopedics, and cardiovascular fields [5][28] 2. JP Morgan Conference Overview - The 44th JP Morgan Health Conference highlighted strategic developments from major global pharmaceutical companies, showcasing their core pipeline progress and key clinical milestones for 2026 [33] - Companies such as Pfizer, Merck, and Eli Lilly presented their focus on advancing clinical trials and launching new products in various therapeutic areas [34][35] 3. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance from January 12 to January 16 showed a decrease of 0.68%, with a total trading volume of 916.83 billion yuan, accounting for 5.35% of the total market [2][36] - The report notes that the sector has shown a year-to-date increase of 7.08%, outperforming both the CSI 300 and ChiNext indices [36]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].

Core Viewpoint - The article highlights the exceptional performance of Shengnuo Biopharmaceuticals, which is expected to achieve a net profit of 152 million to 190 million yuan in 2025, marking a year-on-year increase of 204.42% to 280.53% [6]. Group 1: Company Performance - Shengnuo Biopharmaceuticals' projected net profit for 2025 is significantly higher than market expectations, with a forecasted increase of 1.02 billion to 1.40 billion yuan compared to the previous year [6]. - In contrast, the company's performance in 2024 showed a mere 4.84% revenue growth to 456 million yuan, with a net profit decline of 28.88% to 50.02 million yuan due to pricing pressures and increased R&D investments [6]. - The surge in 2025 is attributed to the overseas demand for GLP-1 raw materials, particularly for drugs like semaglutide and tirzepatide, which has led to a 232.3% increase in raw material revenue [8]. Group 2: Industry Dynamics - The global market for GLP-1 drugs is expanding rapidly, with predictions that the annual demand for GLP-1 raw materials could reach 50 tons by 2030 [9]. - The expiration of key patents for semaglutide in 2026 is expected to trigger a surge in the development and approval of generic and modified drugs, further increasing demand for raw materials [9]. - Shengnuo Biopharmaceuticals is positioned competitively in the domestic market, with an expected total production capacity of approximately 1.25 tons of peptide raw materials by the end of 2025 [8]. Group 3: Future Outlook - The growth logic for GLP-1 raw materials is anticipated to continue, with a tight supply-demand balance expected to persist in the short term [9]. - The industry is entering a phase of capacity competition, with several companies accelerating production, which may lead to price competition and margin pressure [9]. - Shengnuo Biopharmaceuticals' success in 2025 is seen as a result of strategically capitalizing on the global demand for GLP-1 raw materials, rather than a mere short-term luck [9].